Coherus Oncology (CHRS) Other Working Capital Changes (2013 - 2026)

Coherus Oncology has disclosed Other Working Capital Changes across 14 years of filings, most recently posting -$4.5 million for Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$4.5 million, down 622.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.7 million (down 509.27% YoY), and the FY2025 annual result was -$10.3 million, down 12695.12% from the prior year.
• Other Working Capital Changes came in at -$4.5 million for Q1 2026 at Coherus Oncology, down from $2.3 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $7.7 million in Q2 2024 to a low of -$13.5 million in Q3 2025.
• The 5-year median for Other Working Capital Changes is -$1.4 million (2022), against an average of -$737882.4.
• Across the five-year window, Other Working Capital Changes jumped 553.63% in 2023 and slumped 2744.21% in 2025, its largest moves.
• Coherus Oncology's Other Working Capital Changes stood at -$2.8 million in 2022, then rose by 23.54% to -$2.1 million in 2023, then slumped by 100.67% to -$4.2 million in 2024, then soared by 154.76% to $2.3 million in 2025, then slumped by 293.9% to -$4.5 million in 2026.
• The last three Other Working Capital Changes figures came in at -$4.5 million (Q1 2026), $2.3 million (Q4 2025), and -$13.5 million (Q3 2025), per Business Quant data.